Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 7/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL84852 | 0.84 | HSD11B1 (0.55) | HSD11B1KMT2AMEN1RAB9AKDM4E | |
| SCHEMBL26031379 | 0.83 | HSD11B1 (0.57) | HSD11B1KMT2AMEN1RAB9AKDM4E | |
| SCHEMBL8642977 | 0.83 | — | — | |
| SCHEMBL10972781 | 0.83 | ALDH1A1 (0.50) | KMT2AMEN1RAB9AKDM4EALDH1A1 | |
| SCHEMBL12337282 | 0.81 | KMT2A (0.49) | HSD11B1KMT2AMEN1RAB9AKDM4E | |
| SCHEMBL23471236 | 0.80 | HSD11B1 (0.51) | HSD11B1KMT2AMEN1RAB9AKDM4E | |
| SCHEMBL84384 | 0.80 | HSD11B1 (0.59) | HSD11B1KMT2AMEN1RAB9AKDM4E | |
| SCHEMBL772617 | 0.80 | HSD11B1 (0.51) | HSD11B1KMT2AMEN1RAB9AKDM4E | |
| SCHEMBL229115 | 0.80 | ALDH1A1 (0.60) | HSD11B1KMT2AMEN1RAB9AKDM4E | |
| SCHEMBL22281655 | 0.80 | HSD11B1 (0.51) | HSD11B1KMT2AMEN1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023109883-A1 | AROMATIC HETEROCYCLE-SUBSTITUTED COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翊石医药科技有限公司 | 2023-06-22 | — | — | WO | disclosed |
| US-20210395295-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | ORIC PHARMACEUTICALS, INC. | 2021-12-23 | — | — | US | disclosed |
| US-11124537-B2 | Inhibitors of glucocorticoid receptor | ORIC PHARMACEUTICALS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-11028079-B2 | Small molecule BET bromodomain inhibitors and uses thereof | CONVERGENE, LLC (US) | 2021-06-08 | — | — | US | disclosed |
| US-20210017220-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | ORIC PHARMACEUTICALS, INC. | 2021-01-21 | — | — | US | disclosed |
| US-20200223836-A1 | SMALL MOLECULE BET BROMODOMAIN INHIBITORS AND USES THEREOF | CONVERGENE LLC | 2020-07-16 | — | — | US | disclosed |
| US-9656996-B2 | Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD. (CN) | 2017-05-23 | — | — | US | disclosed |
| US-20160311817-A1 | HETEROARYL SULTAM DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2016-10-27 | — | — | US | disclosed |
| US-20160244432-A1 | FUSED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTCIAL COMPOSITION, AND USES THEREOF | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD. (CN) | 2016-08-25 | — | — | US | disclosed |
| US-8993563-B2 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8383620-B2 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20130023497-A1 | Triazine Derivatives and their Therapeutical Applications | NANTBIO, INC. | 2013-01-24 | — | — | US | disclosed |
| US-20120238576-A1 | Triazine Derivatives and their Therapeutical Applications | CALIFORNIA CAPITAL EQUITY, LLC (CA) | 2012-09-20 | — | — | US | disclosed |
| US-20120178758-A1 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120172361-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-07-05 | — | — | US | disclosed |
| US-20110150763-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | ABRAXIS BIOSCIENCE, LLC (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110097349-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-28 | — | — | US | disclosed |
| US-7858782-B2 | Triazine derivatives and their therapeutical applications | ABRAXIS BIOSCIENCE, LLC (US) | 2010-12-28 | — | — | US | disclosed |
| US-20080176853-A1 | e.g. N-(2-chloro-6-methylphenyl)-3-ethoxyacrylamide; protein (tyrosine and serine/threonine) kinase inhibitor; variety of conditions and diseases; antiproliferative, anticarcinogenic, antiinflammatory, antiallergenic agent; autoimmune and neurodegenerative disorders | ABRAXIS BIOSCIENCE, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| WO-2008070740-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244432-A1 | FUSED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTCIAL COMPOSITION, AND USES THEREOF | PIK3CA, PIK3CD, PIK3R5 | HSD11B1 78/4885KMT2A 3747/4885MEN1 744/4885 |
| US-20120172361-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CYP3A5, CYP11B2, ABCB1 | HSD11B1 319/4885KMT2A 2489/4885MEN1 3723/4885 |
| US-11124537-B2 | Inhibitors of glucocorticoid receptor | NR3C1, NR3C2, MC2R | HSD11B1 19/4885KMT2A 3404/4885MEN1 311/4885 |
| US-20130023497-A1 | Triazine Derivatives and their Therapeutical Applications | IL5, IKZF3, CYP11B2 | HSD11B1 327/4885KMT2A 2444/4885MEN1 4203/4885 |
| US-20160311817-A1 | HETEROARYL SULTAM DERIVATIVES AS RORc MODULATORS | RORC, RORA, RORB | HSD11B1 86/4885KMT2A 553/4885MEN1 4566/4885 |
| US-11028079-B2 | Small molecule BET bromodomain inhibitors and uses thereof | BRDT, BRD4, BRD3 | HSD11B1 2400/4885KMT2A 674/4885MEN1 2729/4885 |
| US-20110097349-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, AKT3, PI4KA | HSD11B1 1208/4885KMT2A 3734/4885MEN1 1932/4885 |
| US-20120178758-A1 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | STK25, STK35, SGK2 | HSD11B1 2870/4885KMT2A 1102/4885MEN1 4391/4885 |
| US-20120238576-A1 | Triazine Derivatives and their Therapeutical Applications | SLC10A1, GLS, SLC10A2 | HSD11B1 250/4885KMT2A 2859/4885MEN1 3798/4885 |
| US-20200223836-A1 | SMALL MOLECULE BET BROMODOMAIN INHIBITORS AND USES THEREOF | BRDT, BRD4, BRD3 | HSD11B1 2400/4885KMT2A 674/4885MEN1 2729/4885 |
| US-20110150763-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | BAZ2A, CAMKK2, BAZ1A | HSD11B1 2698/4885KMT2A 1241/4885MEN1 4476/4885 |
| US-20080176853-A1 | e.g. N-(2-chloro-6-methylphenyl)-3-ethoxyacrylamide; protein (tyrosine and serine/threonine) kinase inhibitor; variety of conditions and diseases; antiproliferative, anticarcinogenic, antiinflammatory, antiallergenic agent; autoimmune and neurodegenerative disorders | MAP3K15, DSTYK, STK25 | HSD11B1 4380/4885KMT2A 790/4885MEN1 2868/4885 |
| US-20210395295-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | NR3C1, NR3C2, MC2R | HSD11B1 19/4885KMT2A 3404/4885MEN1 311/4885 |
| US-20210017220-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | NR3C1, NR3C2, MC2R | HSD11B1 19/4885KMT2A 3404/4885MEN1 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.